Archive for the ‘Hospital Clínic de Barcelona’ Category

Tuesday May 02nd, 2017

FreeOx Biotech acquires the rights of two compounds to treat neurological and cardiovascular diseases

Dr. Ángel Chamorro, Head of the Functional Unit of Cerebral Vascular Pathology at Hospital Clínic de Barcelona, ​​has developed two compounds with neuroprotective properties based on reducing the effects of oxidative stress on the body. Hospital Clínic and the Clínic Foundation for Biomedical Research, with the support of the IDIBAPS’s KTT office (Knowledge and Technology Transfer), have signed an exclusive license agreement with FreeOx Biotech for the development and exploitation of this technology. Read the rest of this entry »

Thursday April 20th, 2017

A study reveals the biological changes in breast cancer between the primary tumor and metastases

A study published in the journal Cancer Research underscores the importance of the molecular characterization of the metastases in breast cancer. Researchers have described, for the first time, that the longer the time from the onset of the tumor to the development of metastasis is, the more aggressive this cancer becomes. They have also shown that between the initial tumor and the metastasis the subtype of breast cancer can change in up to 40% of cases. The work has been coordinated by Aleix Prat, Head of the Oncology Department of the Hospital Clínic, Head of the Translational Genomics team and directed therapies in solid tumors IDIBAPS team and Head of the VHIO Translational Genomics Group. The first author of the study is Juan Miguel Cejalvo, PhD student of the PhD4MD program in the group led by Aleix Prat at IDIBAPS and in the Growth Control and Cancer Metastasis group of the Institute for Research in Biomedicine (IRB Barcelona), led by the ICREA researcher Roger Gomis.

Read the rest of this entry »

Comments Closed
Wednesday April 05th, 2017

Elías Campo takes office as Director of IDIBAPS

Yesterday, Tuesday, April 4th, Elías Campo took office as the new Director of IDIBAPS replacing Ramon Gomis, who has held the position since 2008. The election of the new director was made after an international call and an open selection process. Elías Campo is Research and Innovation Director of Hospital Clínic, Director of the Clinic Foundation and responsible for the group Molecular pathology of lymphoid neoplasms of IDIBAPS. He is also full professor in the Faculty of Medicine and Health Sciences at the University of Barcelona. Read the rest of this entry »

Comments Closed
Monday March 27th, 2017

The IDIBAPS participates in BIO-Europe Spring

The Barcelona International Convention Center hosted from 20-22 March the BIO-Europe Spring conference. This is the most important partnering congress in Europe for the biotechnology and pharmaceutical industry. Attendees had 3 days to hold 30-minute private meetings with other international managers and business developers, from other institutions and companies around the world.

Read the rest of this entry »

Comments Closed
Wednesday March 08th, 2017

A device with mobile games and remote medical monitoring for at-home pelvic floor rehabilitation

As part of the European WOMEN-UP project, in September the Universitat Politècnica de Catalunya and the Hospital Clínic de Barcelona (Spain), along with the Academic Medical Center (the Netherlands) and Kuopio University Hospital (Finland), will carry out the clinical trial of a system designed to improve pelvic floor muscle training, a recommended treatment to prevent or treat urinary incontinence. This technological solution incorporates serious games for mobile phones that are driven by muscle movement and remote medical monitoring through a web platform. Read the rest of this entry »

Comments Closed
Friday February 17th, 2017

A therapeutic HIV vaccine clinical trial induces viral control in 5 people without taking antiretroviral therapy

A therapeutic HIV vaccine clinical trial showed, for the first time, that in some cases the immune system of HIV infected people can be reeducated to control the virus for long periods without taking antiretroviral treatment. In particular, 5 out of 13 participants who stopped treatment (38.5%) have been controlling the virus for 5, 13, 17, 20 and 27 weeks, respectively. The study, still ongoing, is conducted in Barcelona and tests a vaccine developed by researchers at Oxford University in combination with a drug, romidepsin, able to awaken latent viruses in the body. The study is conducted by IrsiCaixa and the Fight AIDS Foundation and performed at the ospital Clínic de Barcelona-IDIBAPS, the Germans Trias i Pujol University Hospital (Barcelona) and the community center BCN Checkpoint. Read the rest of this entry »

Comments Closed
Page 1 of 5612345...Last »